Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series

Keyphrases

• Stage III Non-small Cell Lung Cancer 100%
• Thoracic Radiation 100%
• Without Chemotherapy 100%
• Programmed Death-ligand 1 (PD-L1) 75%
• Pembrolizumab 50%
• Cancer Institute 25%
• Maintenance Therapy 25%
• Disease Progression 25%
• Squamous Cell Carcinoma (SqCC) 25%
• Improved Survival 25%
• Adenocarcinoma 25%
• Non-small Cell Lung Cancer Patients 25%
• Complete Response 25%
• Adult Patients 25%
• Brain Metastases 25%
• Cytotoxic Chemotherapy 25%
• Standard of Care 25%
• Poor Performance Status 25%
• Progressive Disease 25%
• Immune Checkpoint Inhibitors 25%
• Chemoradiation 25%
• Retrospective Case Series 25%
• Definitive Chemoradiation 25%
• Stage IIIC 25%
• Chemotherapy Toxicity 25%
• Concurrent Chemoradiation 25%
• Case Series Report 25%
• Durvalumab 25%
• Programmed Death-ligand 1 Expression 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Chemotherapy 100%
• Immunotherapy 100%
• Chemoradiation Therapy 75%
• Programmed Death 1 Ligand 1 75%
• Pembrolizumab 50%
• Diseases 50%
• Malignant Neoplasm 25%
• Disease Exacerbation 25%
• Squamous Cell Carcinoma 25%
• Adenocarcinoma 25%
• Cytotoxic Chemotherapy 25%
• Brain Metastasis 25%
• Immune Checkpoint Inhibitor 25%
• Death Receptor 25%
• Durvalumab 25%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Immunotherapy 100%
• Chemoradiotherapy 75%
• Programmed Death 1 Ligand 1 75%
• Pembrolizumab 50%
• Malignant Neoplasm 25%
• Maintenance Therapy 25%
• Adenocarcinoma 25%
• Disease Exacerbation 25%
• Brain Metastasis 25%
• Cytotoxic Chemotherapy 25%
• Squamous Cell Carcinoma 25%
• Immune Checkpoint Inhibitor 25%
• Death Receptor 25%
• Progressive Disease 25%
• Diseases 25%
• Durvalumab 25%